Collectively, these findings suggest that P2X4 antagonists could serve as novel anti‐psychotic treatments for psychiatric disorders arising from sensorimotor gating impairments linked to the disruption of DA homeostasis. This evidence concerns the gene P2RX4 and psychiatric disorder.